NCT04361552 is a Phase 3 clinical trial of Best Practice in Cerebrovascular Accident, sponsored by Emory University.

Who is sponsoring NCT04361552?

NCT04361552 is sponsored by Emory University.

What drugs are being tested in NCT04361552?

Interventions in NCT04361552: Best Practice, Tocilizumab.

What condition does NCT04361552 study?

NCT04361552 studies Cerebrovascular Accident, Chronic Obstructive Pulmonary Disease, Chronic Renal Failure, Coronary Artery Disease, Diabetes Mellitus, Malignant Neoplasm, SARS Coronavirus 2 Infection.

Is NCT04361552 still recruiting?

NCT04361552 is currently withdrawn. Last updated 18 June 2020.

Last reviewed 2020-06-18 · How we verify

NCT04361552

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection)

Withdrawn Phase 3 Last updated 18 June 2020

What this trial tests

Phase 3 trial testing Best Practice in Cerebrovascular Accident. Withdrawn.

Timeline

7 April 2020

Primary endpoint
2 June 2020

2 June 2020

Quick facts

Lead sponsor	Emory University
Phase	Phase 3
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Start date	7 April 2020
Primary completion	2 June 2020
Estimated completion	2 June 2020
Sites	1 location across United States

Drugs / interventions tested

Best Practice
Tocilizumab (tocilizumab) — full drug profile →

Conditions studied

Cerebrovascular Accident — all drugs for Cerebrovascular Accident →
Chronic Obstructive Pulmonary Disease — all drugs for Chronic Obstructive Pulmonary Disease →
Chronic Renal Failure — all drugs for Chronic Renal Failure →
Coronary Artery Disease — all drugs for Coronary Artery Disease →

Sponsor

Emory University

Who can join

18 and older, any sex, with Cerebrovascular Accident or Chronic Obstructive Pulmonary Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase III trial compares the effect of adding tocilizumab to standard of care versus standard of care alone in treating cytokine release syndrome (CRS) in patients with SARS-CoV-2 infection. CRS is a potentially serious disorder caused by the release of an excessive amount of substance that is made by cells of the immune system (cytokines) as a response to viral infection. Tocilizumab is used to decrease the body's immune response. Adding tocilizumab to standard of care may work better in treating CRS in patients with SARS-CoV-2 infection compared to standard of care alone.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Best Practice

Trials testing the same drug.

NCT07126548 — A Point of Prostate Cancer Diagnosis Virtual Reality Assistant Intervention in Supporting Newly Diagnosed Black Men · NA · not yet recruiting
NCT07022678 — Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia · Phase 3 · not yet recruiting
NCT07225855 — Geriatric Assessment and Management for Older Adults Undergoing Chemotherapy and Radiation Therapy for Head and Neck Can · NA · not yet recruiting
NCT05874297 — Online Nutrition Education to Decrease the Side Effects of Chemotherapy in Patients With Breast Cancer · NA · not yet recruiting
NCT07176000 — Tailored Patient Navigation to Improve the Uptake of Lung Cancer Screening in Tribal Communities in Western Washington S · NA · not yet recruiting

Other recruiting trials for Cerebrovascular Accident

Currently open trials in the same condition.

NCT07272239 — Effects of tVNS and mCIMT in Chronic Stroke · NA · recruiting
NCT06498011 — COgnitive-somatoSensory-MOtor Training to Improve Arm and Hand Function After Stroke (iCOSMO) · NA · recruiting
NCT06521801 — Cardio-Renal Registry · recruiting
NCT06371937 — iPSC Biobank of Biomarkers Diversity in Cardiovascular Disease · recruiting
NCT06107010 — Effects of Atalante Exoskeleton on Gait Recovery in Non- or Poorly Ambulatory Patients With Hemiparesis in the Acute/Sub · NA · recruiting

Other Emory University trials

Trials by the same sponsor.

NCT06143345 — HIIT in Isolated IFG: A Proof-of-Concept Study · NA · withdrawn
NCT07189819 — Innovative Closed-loop Functional Electrical Stimulation Control System for Augmenting Post-stroke Gait · NA · not yet recruiting
NCT06451055 — Low-calorie Diet in Isolated Impaired Fasting Glucose · NA · not yet recruiting
NCT07405476 — Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative I · Phase 2 · recruiting
NCT06708351 — Enhancing Cervical Cancer Screening and Treatment in Women Living With HIV in Kenya, the ENHANCE LINKAge Trial · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04361552 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Emory University
Last refreshed: 18 June 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04361552.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing